Die Discussion Papers dienen einer möglichst schnellen Verbreitung von neueren Forschungsarbeiten des ZEW. Die Beiträge liegen in alleiniger Verantwortung der Autoren und stellen nicht notwendigerweise die Meinung des ZEW dar.Discussion Papers are intended to make results of ZEW research promptly available to other economists in order to encourage discussion and suggestions for revisions. The authors are solely responsible for the contents which do not necessarily represent the opinion of the ZEW.Download this ZEW Discussion Paper from our ftp server:ftp://ftp.zew.de/pub/zew-docs/dp/dp0560.pdf
Non-technical SummaryThe biotechnology industry still has considerable expectations concerning its growth rates in employment, new products, patents and profits. In this paper we analyze if R&D policy in private business, respective public funding in biotechnology lost its origins, its mission and in the end its power. We assume that too many technologies and their increasing complexity overtax policy makers as much as their staff to follow their own strategies. It is assumed that authorities and public funding agencies neglect 'risk' as most important triggers for public R&D funding: it becomes arbitrary. We assume that public R&D funding degenerates in a public policy without discriminating between firms which suffer from financial risk, technical risk or market risk. Today, and especially in biotechnology, every firm which likes to be funded will be funded, because the R&D policy does not care for different risks any longer. Bureaucrats and experts decide by their own which projects and firms will be funded and become totally screwed on the target population.This study combines data of all German biotech companies and all publicly funded R&D biotech projects on the firm level from 2000 to 2003. The survey contains data of 1,529 firms from the largest German credit rating agency called "Creditreform" as much as missionorientated R&D project data of 326 firms from the Federal Ministry for Research and Education (BMBF). The BMBF funding data on R&D projects in the field of Biotechnology remains the most important and extensive instrument to foster R&D in Germany. We carry out Probit and Tobit estimations to determine public funded R&D. In the estimated models we control e.g. for industries, age, credit history, turnover, legal form, patents as well as for particular business fields which might have influence on the probability to receive public R&D subsidies.
Public R&D policy: The right turns of the wrong screw? The case of the German Biotechnology IndustryAndreas Fier and Oliver Heneric 1Centre for European Economic Research (ZEW), Mannheim Abstract The German biotechnology industry missed the accession of this key technology in the 1980s. Policy makers make different efforts to overcome shortcomings and recent gaps. Public funding schemes have been implemented to establish a flourish biotech industry in Germany. We assume that R&D policy was driven blind by the idea to catch up with world's biotech leaders and analyse i...